Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IZN-6D4 is a topical hydrogel formulation containing naturally derived pharmaceutical ingredients, including plant extracts, developed for the treatment of diabetic foot ulcers. The drug is designed to improve wound healing in patients with diabetic foot ulcers who have elevated levels of metalloproteinases in their wounds. It acts by impacting growth factors and extracellular matrix components involved in wound repair. Clinical studies have shown that IZN-6D4 accelerates wound healing and leads to significant improvement in wound closure compared to placebo hydrogels. The product was developed by Izun Pharmaceuticals Corporation as a potential first-line treatment for hard-to-heal wounds[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IZN-6D4.